03:39 AM EDT, 08/27/2026 (MT Newswires) -- AbbVie (ABBV.VI) filed an application to allow Skyrizi as a subcutaneous induction to treat moderately to severely active Crohn's disease in adult patients. The submission to the European Medicines Agency was based on the pharmaceutical company's Affirm phase 3 study, which reviewed Skyrizi's safety and efficacy as an induction treatment, according to a Thursday release. The approval will let Skyrizi be used as an injection or IV infusion for Crohn's disease treatment.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.